Oncode Institute and Centre for Molecular Medicine, UMC Utrecht, Utrecht, Netherlands.
Oncode Institute and Centre for Molecular Medicine, UMC Utrecht, Utrecht, Netherlands
Life Sci Alliance. 2024 Jul 5;7(9). doi: 10.26508/lsa.202402575. Print 2024 Sep.
The transmembrane E3 ligases RNF43 and ZNRF3 perform key tumour suppressor roles by inducing endocytosis of members of the Frizzled (FZD) family, the primary receptors for WNT. Loss-of-function mutations in and mediate FZD stabilisation and a WNT-hypersensitive growth state in various cancer types. Strikingly, and mutations are differentially distributed across cancer types, raising questions about their functional redundancy. Here, we compare the efficacy of RNF43 and ZNRF3 of targeting different FZDs for endocytosis. We find that RNF43 preferentially down-regulates FZD1/FZD5/FZD7, whereas ZNRF3 displays a preference towards FZD6. We show that the RNF43 transmembrane domain (TMD) is a key molecular determinant for inducing FZD5 endocytosis. Furthermore, a TMD swap between RNF43 and ZNRF3 re-directs their preference for FZD5 down-regulation. We conclude that RNF43 and ZNRF3 preferentially down-regulate specific FZDs, in part by a TMD-dependent mechanism. In accordance, tissue-specific expression patterns of FZD homologues correlate with the incidence of or cancer mutations in those tissues. Consequently, our data point to druggable vulnerabilities of specific FZD receptors in - or -mutant human cancers.
跨膜 E3 连接酶 RNF43 和 ZNRF3 通过诱导 WNT 主要受体卷曲蛋白(FZD)家族成员的内吞作用,发挥关键的肿瘤抑制作用。和 中的失活功能突变介导 FZD 的稳定和各种癌症类型中的 WNT 超敏生长状态。引人注目的是,和 突变在癌症类型中存在差异分布,这引发了它们功能冗余的问题。在这里,我们比较了 RNF43 和 ZNRF3 靶向不同 FZD 进行内吞作用的效果。我们发现 RNF43 优先下调 FZD1/FZD5/FZD7,而 ZNRF3 则显示出对 FZD6 的偏好。我们表明,RNF43 的跨膜结构域(TMD)是诱导 FZD5 内吞作用的关键分子决定因素。此外,RNF43 和 ZNRF3 之间的 TMD 交换将它们对 FZD5 下调的偏好重新定向。我们得出结论,RNF43 和 ZNRF3 优先下调特定的 FZD,部分是通过 TMD 依赖性机制。相应地,FZD 同源物的组织特异性表达模式与这些组织中 或 癌症突变的发生率相关。因此,我们的数据表明,在 -或- 突变的人类癌症中,特定 FZD 受体存在可靶向的脆弱性。
Life Sci Alliance. 2024-9
EMBO Rep. 2021-5-5
Cell Commun Signal. 2020-6-11
Contact (Thousand Oaks). 2025-7-28
Nat Rev Mol Cell Biol. 2025-5
Cell Mol Gastroenterol Hepatol. 2021